Endpoint
STAR-01
ACCORD
12/0405
CAO/ARO/
AIO-04
NSABP
R-04
PETACC-6
PCR
16%
both
arms
14%
vs 19%
12.8%
vs
16.5%
(p=0.038)
19% vs
21%
11.5%
vs
13%
CRM
4%
vs 7%
8%
vs 13%
5%
vs 6% No data
2%
vs 2%
Oxaliplatin Phase III trials:
Control arm in red